-
Product Insights
Seizures – Drugs In Development, 2023
Global Markets Direct’s, ‘Seizures - Drugs In Development, 2023’, provides an overview of the Seizures pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) - Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Status Epilepticus – Drugs In Development, 2023
Global Markets Direct’s, ‘Status Epilepticus - Drugs In Development, 2023’, provides an overview of the Status Epilepticus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Profile
SciSparc Ltd – Company Profile
SciSparc Ltd (SciSparc), formerly Therapix Biosciences Ltd, is a clinical-stage biopharmaceutical company which focuses on the development of cannabinoid-based pharmaceuticals for the treatment of central nervous system disorders. SciSparc’s major product candidates include SCI-110, for the treatment of Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Alzheimer’s disease and agitation, SCI-210, for the treatment of Autism Spectrum Disorder (ASD) and epilepsy, and SCI-160, for the treatment of pain. The company conducts its clinical programs in collaboration with various pharma companies...
Add to Basket -
Product Insights
Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder – Drugs In Development, 2022, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape. Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that...
-
Product Insights
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive...
-
Product Insights
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. The traumatic brain injury drugs in development market research report provides an overview...